Compare Amgen, Inc. (AMGN) vs Direxion Daily Semiconductor Bear 3X Shares (SOXS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Direxion Daily Semiconductor Bear 3X Shares — how do they compare? Amgen, Inc. trades at $415.43 (market cap $224.14B), while Direxion Daily Semiconductor Bear 3X Shares trades at $39.98. The key difference: Amgen, Inc. pays a 2.43% dividend while Direxion Daily Semiconductor Bear 3X Shares pays none. Which is the better fit depends on your goals.
| AMGN | SOXS | |
|---|---|---|
Market Cap | $224.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $417.20 | $1.49K |
52-Week Low | $271.18 | $32.50 |
Enterprise Value | $267.45B | — |
Dividend Yield | 2.43% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Amgen (AMGN) trades at $416.74, showing minimal daily movement with a slight 0.11% decline. The stock maintains strong technical momentum with bullish moving averages and support at $412. Fundamentally, the company demonstrates robust performance with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, while revenue growth continues with 2025 revenue reaching $36.75 billion. Analyst sentiment remains positive with 59% buy ratings, though the current price exceeds the consensus target of $394.69.
Amgen presents a mixed outlook with strong earnings momentum and product growth offset by valuation concerns. Investment opportunities include continued blockbuster drug performance and raised 2026 guidance, while risks involve high debt levels and potential data breach litigation impacts. The stock's current premium valuation requires sustained execution to justify further upside.
SOXS, the Direxion Daily Semiconductor Bear 3X ETF, is trading at $39.97, down 11.59% in the past 24 hours amid a bearish technical signal. The ETF benefits from recent semiconductor sector weakness, with news highlighting its surge during chip stock sell-offs. A 1:10 stock split is scheduled for July 26, 2026, while technical indicators show oversold conditions with RSI at 26.30.
The outlook remains volatile, with SOXS positioned to gain from continued semiconductor sector pressure, though leveraged inverse exposure carries high risk. Key risks include rapid AI-driven chip rallies reversing bearish bets. Investors should weigh sector volatility against the ETF's structure, with support at $41 and resistance at $45.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Direxion Daily Semiconductor Bear 3X Shares
SOXS is a leveraged ETF that seeks daily investment results corresponding to 300% of the inverse (opposite) of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bearish (short) position on the semiconductor sector. Due to the effects of compounding and leverage, SOXS is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXS →
